MedTrace Logo

MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease

NCT04052191 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-10-03

No results posted yet for this study

Summary

Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.

Conditions

Interventions

BIOLOGICAL

MCRcI® stem cells

Intra-Coronary Administration of MCRcI® stem cells

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Honya Medical Inc

    lead INDUSTRY

Principal Investigators

  • Fang Y Lee, MD · Chang Gung Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-01-01
Completion
2026-12-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04052191 on ClinicalTrials.gov